2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5224 The prognostic effect of multi-hit TP53 attenuates with increasing blast burden but persists in acute myeloid leukemia (AML): A pooled analysis across the myelodysplastic syndrome (MDS)-AML spectrum

Paloma Resende, MD, Andre Meireles, MD2, Tarcila Santos Datoguia, MD3, Amanda Ennes Inacio Dias dos Santos, MD4, Kira Bucci, MD5, Juliana Dall Agnol Rocha, MD6, André Dias Américo, MD7, Luiz Ferreira Cortes8, Alexandre Eiji Eiji Kayano, MD9, Luana Nobrega, MD10, Frederico Honorato Honorato Jr, MD11, Jade Zezzi Martins do Nascimento, MD12, Carolina Perrone Marques Ferreira, MD13, Elvira Velloso Sr, Dr14, Paulo Vidal Campregher, MD, PhD15, Nelson Hamerschlak Sr, MD PhD16, Fabio Pires S Santos, MD, PhD17
1 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
2 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
3 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
4 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
5 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
6 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
7 BP - A Beneficência Portuguesa de São Paulo, Sao Paulo, Brazil
8 Einstein Hospital Israelita, Sao Paulo, Brazil, Genesis Genomics, Sao Paulo, Brazil
9 Einstein Hospital Israelita, Sao Paulo, Brazil, Hospital das Clínicas da FMUSP, Sao Paulo, Brazil
10 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
11 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
12 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
13 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
14 Einstein Hospital Israelita, Sao Paulo, Brazil, Hospital das Clínicas da FMUSP, Sao Paulo, Brazil
15 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil, Genesis Genomics, Sao Paulo, Brazil
16 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
17 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil

Background: The 2022 WHO and ICC classifications treat TP53 allelic state differently as blast counts rise. WHO 2022 requires multi-hit status to define a specific MDS entity but does not define a TP53-mutated AML category. In contrast, the ICC requires multi-hit status only in patients with less than 10% blasts. Whether the prognostic effect of a second TP53 hit changes continuously with blast burden remains uncertain. We examined the prognostic effect of multi-hit TP53 across the full spectrum of marrow blast counts in MDS and AML.

Methods: We pooled 14 published myeloid cohorts comprising 15,972 patients, including 1,067 with a TP53 mutation. The primary analysis included 676 patients with MDS or AML who had overall survival, age, measured marrow blasts, and TP53 variant allele frequency available (570 deaths). Confirmed multi-hit TP53 was defined as ≥2 distinct functional variants, one variant plus any 17p abnormality, or one variant with VAF >55%. The comparator was a single TP53 mutation without a detected second hit. We modeled blasts continuously using an age-adjusted Cox model with restricted cubic splines, including a blast-by-multi-hit interaction and stratifying the baseline hazard by study.

Results: The prognostic effect of confirmed multi-hit TP53 varied with blast burden (interaction LRT p=0.001). The estimated HR for multi-hit versus single-mutation disease decreased from 3.91 (95% CI, 2.58–5.92) at 2% blast s to 1.91 (1.39–2.65) at 10% and 1.32 (0.91–1.92) at 20%. Most of the attenuation occurred below 20% marrow blasts; the estimated effects at 20% and 50% blasts did not differ (p=0.552). At <5% blasts, median OS was 13.9 months for multi-hit disease and 60.1 months for single-mutation disease. At ≥20% blasts, median OS was 4.5 and 8.0 months, respectively. In AML alone (n=372), multi-hit TP53 remained associated with inferior OS, although the effect was modest (HR 1.31, 95% CI 1.01–1.70; median OS, 4.6 vs 7.0 months). In a categorical analysis restricted to patients with ≥20% blasts, multi-hit status also remained adverse (HR 1.39, 95% CI 1.06–1.83). Adjustment for complex karyotype reduced the estimated HR at 5% blasts from 2.91 to 1.91, but the blast-by-multi-hit interaction remained significant (p=0.004). The interaction remained significant across all 11 prespecified sensitivity analyses (all p≤0.004).

Conclusions: The prognostic effect of multi-hit TP53 varies with blast burden, with a steep attenuation below 20% blasts and a smaller but still detectable effect in AML. These findings argue against a discrete blast threshold beyond which TP53 allelic state loses prognostic relevance. The large effect estimated at low blast counts requires independent validation, and adjustment for complex karyotype attenuates but does not eliminate the interaction.

Paloma Resende, MD: BeOne - Honoraria; CSL Behring - Honoraria